Spero Therapeutics (SPRO) News Today $1.03 -0.04 (-3.72%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below Two Hundred Day Moving Average - Should You Sell?Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Below 200-Day Moving Average - What's Next?December 13, 2024 | marketbeat.comHC Wainwright Issues Pessimistic Estimate for SPRO EarningsSpero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) - Research analysts at HC Wainwright lowered their FY2024 earnings estimates for Spero Therapeutics in a report released on Monday, December 2nd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share ofDecember 4, 2024 | marketbeat.comBuy Rating Reiterated for Spero Therapeutics Amid Promising Trial Progress and Strategic PartnershipDecember 3, 2024 | markets.businessinsider.comTD Cowen Downgrades Spero Therapeutics (SPRO)November 19, 2024 | msn.comSpero Therapeutics downgraded to Hold from Buy at TD CowenNovember 18, 2024 | markets.businessinsider.comSpero Therapeutics (NASDAQ:SPRO) Receives Hold Rating from TD CowenTD Cowen restated a "hold" rating on shares of Spero Therapeutics in a research note on Monday.November 18, 2024 | marketbeat.comTD Cowen downgrades Spero Therapeutics (SPRO) to a HoldNovember 18, 2024 | markets.businessinsider.comSpero Therapeutics: Strategic Shift and Earnings UpdateNovember 16, 2024 | markets.businessinsider.comSpero Therapeutics, Inc.: Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business UpdateNovember 15, 2024 | finanznachrichten.deSpero Therapeutics' (SPRO) Overweight Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of Spero Therapeutics in a research note on Friday.November 15, 2024 | marketbeat.comSpero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business UpdateNovember 14, 2024 | globenewswire.comSpero Therapeutics (SPRO) Set to Announce Earnings on ThursdaySpero Therapeutics (NASDAQ:SPRO) will be releasing earnings after the market closes on Thursday, November 14, Zacks reports.November 8, 2024 | marketbeat.comQ3 EPS Estimate for Spero Therapeutics Boosted by AnalystSpero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) - Equities research analysts at HC Wainwright upped their Q3 2024 earnings per share (EPS) estimates for Spero Therapeutics in a research report issued to clients and investors on Monday, November 4th. HC Wainwright analyst R. Selvaraju now forNovember 6, 2024 | marketbeat.comHC Wainwright Lowers Spero Therapeutics (NASDAQ:SPRO) Price Target to $5.00HC Wainwright cut their price objective on Spero Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a research note on Monday.November 4, 2024 | marketbeat.comSpero’s stock slides after antibiotic flops in Phase II trialNovember 1, 2024 | msn.comCambridge biotech pulls plug on lung disease drug, cuts 39% of workforceNovember 1, 2024 | bizjournals.comSpero suspends development of SPR720, to reduce workforce by 39%October 30, 2024 | markets.businessinsider.comSpero Therapeutics Restructures Focus on Key R&D ProjectsOctober 30, 2024 | markets.businessinsider.comSpero Therapeutics Stock Falls 21%, Cuts Jobs, Suspends Pulmonary Treatment Development ProgramOctober 29, 2024 | marketwatch.comSpero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business UpdateOctober 29, 2024 | markets.businessinsider.comSpero to cut 39% of workforce on failed study, stock plunges 20%October 29, 2024 | seekingalpha.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?October 27, 2024 | finance.yahoo.comSpero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024October 16, 2024 | globenewswire.comSpero Therapeutics (NASDAQ:SPRO) Shares Pass Below 200 Day Moving Average - Here's WhySpero Therapeutics (NASDAQ:SPRO) Shares Pass Below 200 Day Moving Average - Should You Sell?October 15, 2024 | marketbeat.comSpero Therapeutics reports promising Phase 1 trial results for NTM-PD drugOctober 4, 2024 | uk.investing.comSpero Therapeutics (NASDAQ:SPRO) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comPromising Clinical Developments Underpin Buy Rating for Spero TherapeuticsOctober 3, 2024 | markets.businessinsider.comSpero Therapeutics Reports Phase 1 Results Show Significant Lung Uptake Of SPR719October 3, 2024 | markets.businessinsider.comSpero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and ChemotherapyOctober 2, 2024 | globenewswire.comSpero Therapeutics (NASDAQ:SPRO) Shares Pass Below Two Hundred Day Moving Average of $1.46Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below Two Hundred Day Moving Average of $1.46September 24, 2024 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Shares Pass Below 200 Day Moving Average of $1.48Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below 200 Day Moving Average of $1.48September 12, 2024 | marketbeat.comSpero Therapeutics to Present at Upcoming September Investor ConferencesSeptember 5, 2024 | finance.yahoo.comSpero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below 200 Day Moving Average of $1.49Spero Therapeutics (NASDAQ:SPRO) Share Price Crosses Below Two Hundred Day Moving Average of $1.49August 27, 2024 | marketbeat.comEarnings call: Spero Therapeutics Q2 2024 update highlights pipeline progressAugust 10, 2024 | ca.investing.comSpero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comHC Wainwright Weighs in on Spero Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:SPRO)Spero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for Spero Therapeutics in a research report issued to clients and investors on Tuesday, August 6th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn (August 8, 2024 | marketbeat.comIndia's Marico says majority of retail distributors resume ops in BangladeshAugust 8, 2024 | uk.finance.yahoo.comSpero Therapeutics Second Quarter 2024 Earnings: Beats ExpectationsAugust 8, 2024 | finance.yahoo.comSath Shukla Sells 17,641 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) StockAugust 8, 2024 | insidertrades.comTD Cowen Upgrades Spero Therapeutics (SPRO)August 7, 2024 | msn.comSath Shukla Sells 14,800 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) StockAugust 7, 2024 | insidertrades.comSpero Therapeutics (NASDAQ:SPRO) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPSSpero Therapeutics (NASDAQ:SPRO - Get Free Report) issued its earnings results on Monday. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.01. The company had revenue of $10.20 million during the quarter, compared to the consensus estimate of $9.80 million. Spero Therapeutics had a return on equity of 35.42% and a net margin of 21.09%. During the same period in the previous year, the firm posted ($0.23) earnings per share.August 6, 2024 | marketbeat.comSpero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business UpdateAugust 6, 2024 | finanznachrichten.deBuy Rating Affirmed on Spero Therapeutics as Drug Pipeline ProgressesAugust 6, 2024 | markets.businessinsider.comSpero Therapeutics (NASDAQ:SPRO) Raised to Buy at TD CowenTD Cowen raised shares of Spero Therapeutics from a "hold" rating to a "buy" rating in a report on Tuesday.August 6, 2024 | marketbeat.comCantor Fitzgerald Reiterates Overweight Rating for Spero Therapeutics (NASDAQ:SPRO)Cantor Fitzgerald reiterated an "overweight" rating on shares of Spero Therapeutics in a research report on Tuesday.August 6, 2024 | marketbeat.comSpero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business UpdateAugust 5, 2024 | globenewswire.comSpero Therapeutics (SPRO) to Release Earnings on MondaySpero Therapeutics (NASDAQ:SPRO) will be releasing earnings after the market closes on Monday, August 5, Zacks reports.July 30, 2024 | marketbeat.comSpero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024July 29, 2024 | globenewswire.comAcadian Asset Management LLC Has $1.31 Million Holdings in Spero Therapeutics, Inc. (NASDAQ:SPRO)Acadian Asset Management LLC raised its position in shares of Spero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) by 121.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 762,598 shares of thJuly 26, 2024 | marketbeat.com Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Vacuum up cash with these special trades? (Ad)Have you ever heard about a “volatility vacuum?” Most people haven’t. It all revolves around this formula right here. Now, the most important thing is that this equation — when applied to certain tickers at a certain time each month —- can trigger these “volatility vacuums.” And when that happens, anyone has the shot at sucking out payouts of $290, $350, even $1,350 in as little as 24 hours. (With just a $1k starting stake!) Granted, there were smaller wins and those that did not work out but best of all, we can know exactly when these opportunities will hit. I’ve used this info to create a Cash Calendar that lays out the precise dates of these payouts. And I’m sending it for FREE to anyone who joins me during my FREE training right here. SPRO Media Mentions By Week SPRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRO News Sentiment▼-0.130.71▲Average Medical News Sentiment SPRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRO Articles This Week▼12▲SPRO Articles Average Week Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aurora Cannabis News Fate Therapeutics News Lexeo Therapeutics News DiaMedica Therapeutics News Zentalis Pharmaceuticals News Atai Life Sciences News Tenaya Therapeutics News Aclaris Therapeutics News Acrivon Therapeutics News SOPHiA GENETICS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SPRO) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
